MedTrace Logo

Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease

NCT01489228 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2011-12-21

No results posted yet for this study

Summary

This study will assess the safety and efficacy of E1224, a pro-drug of ravuconazole, in individuals with chronic indeterminate Chagas disease recruited in research centres in Tarija and Cochabamba, Bolivia.

Conditions

  • Chronic Chagas Disease, Indeterminate

Interventions

DRUG

E1224

100 mg tablets

DRUG

Benznidazole

100mg tablets

DRUG

Placebo

tablets

Sponsors & Collaborators

  • Eisai Co., Ltd.

    collaborator INDUSTRY

  • Drugs for Neglected Diseases

    lead OTHER

Principal Investigators

  • Isabela Ribeiro, MD · Drugs for Neglected Diseases initiative

  • Faustino Torrico, PhD · Universidad Mayor San Simón. Cochabamba, Bolivia.

  • Joaquim Gascón, PhD · CRESIB - Centre de Recerca en Salut Internacional de Barcelona, Spain.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-08-31
Completion
2013-12-31

Countries

  • Bolivia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01489228 on ClinicalTrials.gov